Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
  • Subscribe
Submit An Article

gary phillips

  • Home
  •  
  • gary phillips



  • Most Read
  • Latest Comments
  • Fibrosis is the simple disease process that’s more important than you think
    • News

    Pandemic poses opportunity to online learning platform OpenLearning
    Public
  • Fibrosis is the simple disease process that’s more important than you think
    • News

    Novatti partners with Ripple for global blockchain payments network
    Public
  • Fibrosis is the simple disease process that’s more important than you think
    • Opinion

    Is ASX: OOO the riskiest or smartest oil investment?
    Public
  • Fibrosis is the simple disease process that’s more important than you think
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Fibrosis is the simple disease process that’s more important than you think
    Crowd Media adds voice cloning for immersive celebrity experiences in AI deal
    • Review
    • January 27, 2021
  • Retired NFL players endorse Zilosul, Paradigm’s osteoarthritis drug trials
    • Review
    • March 24, 2020
  • Research Note - Rise of the Cashless Economy
    • Review
    • June 3, 2020
  • Novatti to drive Malaysia into the digital payments era with ATX acquisition
    • Review
    • October 20, 2021
  • Apiam expands equine vet footprint in Queensland in time for breeding season
    • Review
    • June 30, 2021

Latest Articles

  • Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler
    Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler
    • News

  • Emerald Financial Research Note Update – Pharmaxis Ltd
    Emerald Financial Research Note Update - Pharmaxis Ltd
    • Opinion

  • This small cap biotech is working with Professor Fiona Wood to unscar skin scars, and mainstream media is taking note
    This small cap biotech is working with Professor Fiona Wood to unscar skin scars, and mainstream media is taking note
    • News

  • Fibrosis is the simple disease process that’s more important than you think
    Fibrosis is the simple disease process that’s more important than you think
    • News

  • The Cancer Index: Why investing in oncology biotechs is more science than art
    The Cancer Index: Why investing in oncology biotechs is more science than art
    • News

  • Fibrosis is the simple disease process that’s more important than you think
    • News

    Fibrosis is the simple disease process that’s more important than you think

    How does a company with a lead asset cancer drug also get into dermatology?  What does blood cancer and keloid scars have in common?  The answer is: fibrosis.  Fibrosis is another word for scarring. It is the key in the process of healing where connective tissue replaces normal tissue to form scar tissue. It’s how

    Read More
    Public
  • Shareholders back Pharmaxis liver cancer treatment trials via oversubscribed capital raise
    • News

    Shareholders back Pharmaxis liver cancer treatment trials via oversubscribed capital raise

    When the University of Rochester came knocking on the door of biopharmaceutical company Pharmaxis (ASX: PXS), it was a boost from a respected group of researchers for their lead drug candidate PXS-5505 which has continued to draw attention from around the world.  By agreement with Pharmaxis, the University of Rochester embarked on preclinical work on 

    Read More
    Public
  • This small biotech is the definition of a quiet achiever, here’s why it might be time to tune in
    • News

    This small biotech is the definition of a quiet achiever, here’s why it might be time to tune in

    Clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is in a transformation phase as their clinical pipeline progresses towards multiple value inflection points.  With two products already on market, the Company has a great base from which to fund their ongoing clinical product development. Adding to that, the company has just completed a capital raise viaRead More
    Public
  • Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials
    • News

    Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials

    Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors with positive track records in companies such as Viralytics, Ophthea and Avita committed $7.2 million towards funding the trials for Pharmaxis (ASX: PXS) and their hero drug PXS-5505. Unlike other cancer treatment drugs on the

    Read More
    Public
  • Cancer drug development company gathering momentum as more researchers worldwide take notice
    • News

    Cancer drug development company gathering momentum as more researchers worldwide take notice

    With promising data starting to flow from clinical trials, more and more medical researchers are tuning in to the Pharmaxis (ASX: PXS) story. The drug development Company has a diverse pipeline backed by solid science with drugs engineered by their world renowned drug development team. Lead drug candidate PXS-5505 is designed to treat myelofibrosis, aRead More
    Public
  • Small Caps Watch: Pharmaxis CEO Gary Phillips
    • Opinion

    Small Caps Watch: Pharmaxis CEO Gary Phillips

    Sitting down with Gary Phillips reminds me of chatting to my favourite chemistry teacher in high school. Not that you’d usually compare a biotech company CEO to a past teacher but much like Mr McLeod, Gary has the unique ability to get you excited about science. Gary heads up Pharmaxis (ASX: PXS), a Sydney-based biotechnologyRead More
    Public
  • 1
  • 2

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

Copyright © 2020 The Sentiment. All rights reserved.